Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
OCIAD1 antisense RNA 1 (OCIAD1-AS1) is a human long non-coding RNA transcribed from the antisense strand to the OCIAD1 gene locus[1][7]. It is classified as an antisense lncRNA, and while it has been associated with CD45 deficiency, its precise biological functions, molecular mechanisms, and clinical relevance remain largely uncharacterized[1]. There is no current evidence that OCIAD1-AS1 is a direct therapeutic target, nor are there known drugs or mechanisms of action targeting this RNA specifically. The protein-coding gene OCIAD1, to which this lncRNA is antisense, functions in mitochondrial biology and cell differentiation, but the functional relationship between OCIAD1-AS1 and OCIAD1 has not been elucidated[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on OCIAD1 antisense RNA 1 (OCIAD1-AS1).